Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Horizon Pharma Inc updates on FY 2014 outlook


Wednesday, 19 Mar 2014 07:00am EDT 

Horizon Pharma Inc:Expects FY 2014 pro forma combined revenues of $250 to $265 mln.Expects FY 2014 pro forma combined EBITDA of $65 to $75 mln. 

Company Quote

13.44
0.355 +2.71%
19 Dec 2014